Between July 3 and July 9, 2025, China’s National Medical Products Administration published Announcement No. 63, a policy document introducing ten specific measures to support the development and commercialization of high-end medical devices. Surgical robots and rehabilitation robots are named explicitly as priority categories — a designation that carries practical significance for how device applications are processed and how domestic manufacturers navigate the regulatory pipeline.
The Ten Measures in Summary
Announcement No. 63 addresses the full product lifecycle, from pre-market submission through post-market change management. The ten measures cluster into three functional areas.
Pre-market review acceleration. The announcement reinforces and expands the scope of expedited review procedures for high-end devices, with an emphasis on products in named priority categories. Devices classified as high-end and categorized under priority specialties receive dedicated review queues separate from standard Class III submissions. This builds on the existing Innovation Medical Device Green Channel (创新医疗器械特别审查程序) established in 2014 and revised in 2018, which already provided an accelerated track for devices meeting novelty and clinical need criteria. Announcement No. 63 extends preferential review treatment to a broader set of high-end devices that may not meet the Green Channel’s novelty threshold but are classified in strategic categories.
Lifecycle monitoring simplification. Post-market surveillance requirements under the standard Class III framework impose ongoing reporting obligations that have historically created compliance burdens for manufacturers with broad installed bases. The announcement introduces simplified reporting pathways for certain post-market changes and adverse event categorizations for devices in the priority list. The practical effect is to reduce the administrative overhead of maintaining market authorization for established products while still satisfying the safety monitoring objectives of the post-market framework.
Accelerated post-market change procedures. Medical device manufacturers routinely need to update software, materials, or manufacturing processes after initial approval. Under the standard framework, each change category has a prescribed submission pathway — some requiring full pre-market review, others requiring only record-filing. Announcement No. 63 introduced streamlined procedures for post-market changes affecting priority-category high-end devices, in particular changes that do not affect safety or performance but are triggered by manufacturing optimization or supply chain adjustments.
The announcement also addresses registration standard alignment with international frameworks, clinical trial guidance for novel device categories, and coordination mechanisms between NMPA review centers and device manufacturers during the pre-submission phase.
Why Surgical and Rehabilitation Robots Are Named
The explicit naming of surgical robots and rehabilitation robots as priority categories in Announcement No. 63 reflects their position within China’s medical device import substitution and export development strategy. Both segments share a common policy characteristic: they are high-value, high-complexity categories where domestic manufacturers have made substantial development progress but face a market structure historically dominated by imported equipment.
For surgical robots specifically, the domestic approval landscape had expanded substantially by mid-2025. MicroPort MedBot held six approved platforms (a seventh, the UniPath bronchoscopic robot, was added in December 2025). Surgerii had received NMPA clearance for the SHURUI single-port system. WeMed Medical had obtained approval for the ETcath coronary interventional system. Tinavi, Edge Medical, and other domestic players held multi-port laparoscopic or orthopedic robot approvals. The regulatory priority designation gives this expanding cohort of domestic manufacturers a procedural advantage over foreign competitors seeking equivalent Class III approvals for surgical robot products in China.
For rehabilitation robots, the policy context is the aging population demographic pressure on China’s healthcare system. Stroke and orthopedic rehabilitation demand is projected to grow substantially over the next decade. Domestic rehabilitation robot manufacturers — many developing exoskeleton and assisted-gait platforms — have faced Class III approval timelines that can extend three to five years from initial submission. A more favorable review pathway for this category, per Announcement No. 63, would accelerate the commercial deployment of approved platforms.
The Innovation Green Channel Relationship
China’s Innovation Medical Device Green Channel predates Announcement No. 63 and operates on different criteria. The Green Channel prioritizes devices that represent genuine technical novelty — products with new principles, new materials, or clinical applications without existing market precedent in China. Successful Green Channel applications receive dedicated review teams and compressed timelines, typically targeting twelve months from acceptance to approval decision.
Announcement No. 63’s measures are additive rather than replacing the Green Channel. A device that qualifies for Green Channel treatment retains those benefits; devices that do not meet Green Channel novelty thresholds but are in priority categories under Announcement No. 63 gain access to the preferential procedures introduced in the new policy. The practical result is a more graduated preference structure: Green Channel devices receive the most favorable treatment, followed by Announcement No. 63 priority-category devices, followed by standard Class III review.
The distinction matters because not all surgical robot applications are genuinely novel. A third generation of a domestic multi-port laparoscopic robot with incremental design changes might not qualify for the Green Channel’s novelty standard. Under Announcement No. 63, such a device would still benefit from expedited review as a surgical robot in the priority category.
Implications for Foreign vs. Domestic Manufacturers
Announcement No. 63’s priority treatment applies based on device category, not manufacturer origin — the text does not restrict benefits to domestically developed devices. In principle, a foreign manufacturer submitting a surgical robot application to the NMPA could access the same expedited review procedures.
In practice, however, several structural factors limit the symmetry. The post-market change simplification procedures are most valuable for manufacturers with established products and growing installed bases in China. Foreign manufacturers with surgical robot products already approved in China — Intuitive Surgical being the primary example with the da Vinci system — have established approval and change management workflows built around the pre-Announcement No. 63 framework and may derive limited incremental benefit from the new procedures.
New foreign entrants seeking first-time Chinese approval for surgical robot platforms face the same fundamental submission requirements as domestic applicants. The priority review queue does not waive clinical data requirements or reduce the evidentiary standards for Class III device approval. What it modifies is the administrative processing timeline, not the clinical evidence threshold.
For domestic manufacturers, the announcement’s value is concentrated in two areas: the lifecycle monitoring simplification reduces ongoing compliance costs as product portfolios expand, and the streamlined post-market change procedures reduce the timeline and administrative burden for software and hardware updates — particularly relevant as domestic surgical robot platforms mature and accumulate post-market update needs.
Broader Strategic Context
Announcement No. 63 was issued within the framework of China’s 2025 high-end medical device development strategy, a multi-ministry initiative that has been characterized in policy communications as one of the implementation vehicles for import substitution in strategic medical equipment categories. China Briefing’s analysis of the announcement situated it within this broader industrial policy context, noting that surgical robots are among the equipment categories where the gap between domestic and imported market share has been most visible in hospital procurement data.
The announcement coincides with an accelerated period of domestic surgical robot commercialization. VCBeat Health’s analysis published in early 2026 noted that overseas orders for Chinese-manufactured endoscopic surgical robots surpassed Chinese hospital installations of the imported da Vinci system in H1 2025 — a data point that, if accurate, would represent a significant commercial inflection for the domestic segment. The regulatory support from Announcement No. 63 is one element in a set of policy instruments that also includes the NHSA’s DRG/DIP payment framework revisions, government procurement preference policies, and capital expenditure support programs for hospitals acquiring domestically developed high-end equipment.
The DRG/DIP framework is particularly relevant for commercial adoption of surgical robots. Reimbursement categorizations that allow robot-assisted procedures to be billed at rates that accommodate the incremental cost of robotic versus conventional approaches determine whether hospitals can sustain robot acquisition economically. The NHSA published its updated DRG/DIP regulations in September 2025; combined with Announcement No. 63’s regulatory priority treatment, the paired policy signals in the second half of 2025 created a more favorable commercial environment for domestic surgical robot manufacturers than had existed at the start of the year.
What Changes in Practice
For companies currently in active NMPA review for surgical or rehabilitation robot products, Announcement No. 63 creates a basis to request priority classification and the associated review queue assignment. The announcement does not automatically reclassify pending applications; manufacturers must affirmatively engage with review center coordinators to access the expedited procedures.
For companies planning future submissions, the policy provides a clearer advance signal about regulatory processing timelines. In a capital environment where the timeline from submission to approval materially affects fundraising sequencing and commercialization planning, a policy-level commitment to faster review for named categories reduces one source of uncertainty in the development schedule.
The announcement does not address reimbursement rates, procurement preference criteria, or the clinical training requirements that also shape real-world adoption rates for surgical robots. Those dimensions remain governed by separate policy instruments at the NHSA, Ministry of Finance, and provincial health commission levels. Announcement No. 63 is a regulatory processing efficiency measure; its commercial impact depends on how the broader policy environment for high-end medical device adoption develops over 2025 and 2026.
See the Surgical Robots hub for an overview of robotically-assisted surgical platforms approved in China.